Showing results (21-30 of 27) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.American Journal of Hematology|April 6, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 TrialNichola Cooper, Catherine M Broome, Yoshitaka Miyakawa, et al.Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.Cancer Research|July 5, 2015
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET SignalingAnna Hultberg, Virginia Morello, Leander Huyghe, et al.The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.Biomedicines|July 2, 2021
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer PatientsPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.Cancer|November 2, 2021
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphomaNicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser, et al.Pageof 3